Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 16/20 | 0.66 |
| ▸ | MMP13 | P45452 | 12/20 | 0.66 |
| ▸ | MMP3 | P08254 | 8/20 | 0.66 |
| ▸ | MMP1 | P03956 | 7/20 | 0.66 |
| ▸ | MMP9 | P14780 | 8/20 | 0.63 |
| ▸ | MMP8 | P22894 | 3/20 | 0.63 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.60 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.60 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.60 |
| ▸ | MMP7 | P09237 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4621504 | 1.00 | MMP2 (0.66) | MMP2MMP13MMP3MMP1MMP9 | |
| SCHEMBL4619626 | 1.00 | MMP2 (0.66) | MMP2MMP13MMP3MMP1MMP9 | |
| SCHEMBL5639380 | 0.88 | MMP2 (0.57) | MMP2MMP13MMP3MMP1MMP9 | |
| SCHEMBL13570807 | 0.88 | MMP2 (0.62) | MMP2MMP13MMP3MMP1MMP9 | |
| SCHEMBL11887788 | 0.88 | MMP2 (0.62) | MMP2MMP13MMP3MMP1MMP9 | |
| SCHEMBL13570499 | 0.88 | MMP2 (0.62) | MMP2MMP13MMP3MMP1MMP9 | |
| SCHEMBL8093833 | 0.87 | SLC1A3 (0.63) | MMP2MMP13MMP3MMP1MMP9 | |
| SCHEMBL7425855 | 0.87 | KEAP1 (0.62) | MMP2MMP13MMP3MMP1MMP9 | |
| SCHEMBL7391079 | 0.87 | KEAP1 (0.62) | MMP2MMP13MMP3MMP1MMP9 | |
| SCHEMBL1565606 | 0.86 | MMP13 (0.58) | MMP2MMP13MMP3MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1884230-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT OR AGENT FOR PREVENTING/AMELIORATING ROUGH SKIN AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-02-06 | — | — | EP | disclosed |
| EP-1147095-B1 | 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH CORP (US) | 2004-08-11 | — | — | EP | disclosed |
| US-6544984-B1 | Treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss. | AMERICAN CYANAMID COMPANY | 2003-04-08 | — | — | US | disclosed |
| EP-1147095-A1 | 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| EP-1051407-A1 | 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000044730-A1 | 2,3,4,5-TETRAHYDRO-1H-[1,4]BENZODIAZEPINE-3-HYDROXAMIC ACID AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| US-6071903-A | ENZYME INHIBITORS OF MATRIX METALLOPROTEINASES (MMPS); ANTITUMOR,-CARCINOGENIC AND -ARTHRITIC AGENTS; OSTEOARTHRITIS; RHEUMATOID DISEASES; DEGENERATIVE CARTILAGE LOSS; LONG-ACTING, ORALLY BIOAVAILABLE NONPEPTIDE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-06-06 | — | — | US | disclosed |
| WO-1999037625-A1 | 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-07-29 | — | — | WO | disclosed |